{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1047.364","meta":{"versionId":"25","lastUpdated":"2016-12-27T01:00:03.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Oncology Nursing Society Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2016-12-27"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.364","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1047.364"}],"version":"20161227","name":"ModerateEmeticRiskCancerMedicationAdelsleukin","title":"Moderate Emetic Risk Cancer Medication Adelsleukin","status":"active","experimental":false,"date":"2016-12-27T01:00:03-05:00","publisher":"Oncology Nursing Society Steward","description":"ONS measure set","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: NCCN Classification of chemotherapeutic medication),(Data Element Scope: Maps to the Medication category of the QDM.),(Inclusion Criteria: Includes Adelsleukin prescribable ingredient. Value ranges  for Adelsleukin 12- 15 million IU/m2 are specified using the MAT tool.),(Exclusion Criteria: Excluded are codes not meeting inclusion criteria)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"70223","display":"Aldesleukin"}]}]},"expansion":{"identifier":"urn:uuid:770e4d5f-0b87-4e86-bf3e-e2f7cd6cd729","timestamp":"2023-12-10T20:54:04-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"70223","display":"aldesleukin"}]}}